Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a
life sciences innovator and exporter, announces that Mr. Anthony J.
Giovinazzo, an accomplished leader in the international life
sciences industry, has joined its Board of Directors.
Mr. Giovinazzo joined the Board of Directors
effective today, and was also appointed as a member of the Audit
Committee and the Human Resources, Compensation & Governance
Committee.
Mr. Giovinazzo has over 40 years of life
sciences experience and is an internationally-recognized expert in
life sciences intellectual property, drug development, and product
commercialization. As CEO of Cynapsus Therapeutics Inc., he
co-invented and led the development and commercialization of the
now Health Canada and U.S. FDA approved Parkinson’s Disease drug
Kynmobi™, acquired by Sunovion Pharmaceuticals for CDN$ 841 million
in 2016. Among other industry awards, he was the inaugural
recipient of the Bloom Burton Award in 2017.
Mr. Giovinazzo is a Chartered Director and is
Audit Committee Certified, both from The Directors College, a
degree granting affiliate of McMaster University. He has also
completed Harvard Business School’s program for Leadership and
Strategy in Pharmaceuticals & Biotech, IMD’s Master of Business
Administration (MBA) program, York University’s Osgoode Hall Law
School Certificate Studies in Canadian Law program, and McMaster
University’s B.A. of Economics and Accounting program. Mr.
Giovinazzo currently serves as executive chairman of Sublimity
Therapeutics (Holdings) Ltd., a private company, as a director of
Pond Technologies Holdings Inc. (TSXV: POND), and as a director of
Titan Medical Inc. (TSX: TMD; NASDAQ: TDMI).
Martin Marino, independent chair of Microbix’s
Board of Directors, commented, “I’m delighted to welcome Anthony on
behalf of Microbix’s Directors, Management, Staff, and
Shareholders. Anthony will add his drive, connectivity, broad
perspectives, and expertise to Microbix’s board-level leadership.
His selection follows a formal process by which a special committee
of our board evaluated multiple qualified candidates.”
Anthony Giovinazzo also remarked about his
decision to join the board, “I’ve observed how Microbix has been
evolving its business and have been impressed. Microbix is now well
advanced with its transformation into an inventor, manufacturer,
and marketer of innovative, proprietary, branded, and regulated
medical devices to support the global diagnostics industry. I look
forward to helping to accelerate the pace of value creation by
Microbix and ensuring that shareholders are fully rewarded.”
Upon his appointment, Mr. Giovinazzo is being
granted 100,000 options to purchase common shares. The options have
an exercise price of $0.46, a term of five years and vest at the
end of three years.
About Microbix
BiosystemsMicrobix develops proprietary biological and
technology solutions for human health and well-being, with about 80
skilled employees and sales growing from a base of approximately $1
million per month. It makes a wide range of critical biological
materials for the global diagnostics industry, notably antigens for
immunoassays and its laboratory quality assessment products (QAPs™)
that support clinical lab proficiency testing, enable assay
development and validation, or help ensure the quality of clinical
diagnostic workflows. Microbix antigens enable the antibody tests
of over 100 international diagnostics companies, while its QAPs are
sold to clinical laboratory accreditation organizations,
diagnostics companies, and clinical laboratories. Microbix QAPs are
now available in over 20 countries, distributed by Alpha-Tec
Systems, Inc., Diagnostic International Distribution S.p.A.,
Labquality Oy, The Medical Supply Company of Ireland, and
R-Biopharm AG. Microbix is ISO 9001 and 13485 accredited, U.S. FDA
registered, Australian TGA registered, Health Canada establishment
licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport media to stabilize
patient samples for lab-based molecular diagnostic testing and
Kinlytic® urokinase, a biologic thrombolytic drug used to treat
blood clots. Microbix is traded on the TSX and OTCQB, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, all discussion regarding
Mr. Giovinazzo or his qualifications, his or others’ views, the
role or actions of the board, Microbix’s business and business
results, goals or outlook, risks associated with financial results
and stability, development projects such as those referenced in its
corporate presentation, regulatory compliance and approvals, sales
to domestic or foreign jurisdictions, engineering and construction,
production (including control over costs, quality, quantity and
timeliness of delivery), foreign currency and exchange rates,
maintaining adequate working capital and raising further capital on
acceptable terms or at all, and other similar statements concerning
anticipated future events, conditions or results that are not
historical facts. These statements reflect management’s current
estimates, beliefs, intentions and expectations; they are not
guarantees of future performance. The Company cautions that all
forward looking information is inherently uncertain and that actual
performance may be affected by a number of material factors, many
of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from
the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit www.microbix.com or www.sedar.com
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905)
361-8910 |
Jim Currie, CFO(905)
361-8910 |
Deborah Honig, Investor
RelationsAdelaide Capital Markets(647) 203-8793
ir@microbix.com |
Copyright © 2020 Microbix Biosystems Inc.
Microbix®, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.Kynmobi™ is a trademark of Sunovion Pharmaceuticals
Inc.
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2023 to Apr 2024